Oral Semaglutide versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4) — VialBase Research

Summary

PIONEER 4 was a head-to-head comparison of oral semaglutide 14 mg versus subcutaneous liraglutide 1.8 mg (and placebo) in adults with type 2 diabetes inadequately controlled on metformin with or without SGLT2 inhibitors. The trial established oral semaglutide as noninferior to injectable liraglutide for glycemic control and superior for weight loss.

Key Findings

• Oral semaglutide 14mg was noninferior to subcutaneous liraglutide 1.8mg for HbA1c reduction (-1.2% vs -1.1%)
• Superior weight loss with oral semaglutide: -4.4 kg vs -3.1 kg (liraglutide) vs -0.5 kg (placebo) at 52 weeks
• Both active treatments superior to placebo for HbA1c and weight
• GI adverse events similar between oral semaglutide and liraglutide
• Oral formulation uses SNAC absorption enhancer technology

Methodology

Phase 3, double-blind, double-dummy RCT. 711 adults randomized 2:2:1 to oral semaglutide 14 mg, subcutaneous liraglutide 1.8 mg, or placebo. 52-week treatment with dose escalation. Primary endpoint: HbA1c change from baseline at 26 weeks. Key secondary: body weight change.

Limitations

• T2DM population — not a weight management trial
• Oral semaglutide requires specific dosing conditions (fasting, minimal water)
• SNAC technology limits co-administration with other medications
• Liraglutide 1.8mg is a lower-potency comparator (not semaglutide SC)
• Higher oral doses (25mg, 50mg) now in development for obesity

Relevance to Content

Relevant for content about oral semaglutide options and the future of non-injectable GLP-1 therapies. The convenience of oral dosing is a significant consumer interest point. Important context for discussing Rybelsus and upcoming higher-dose oral formulations.

See Also

• Parent compound: Semaglutide
• Liraglutide